Oramed Pharmaceuticals Inc. - 10-Q Summary
Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc. (Nevada corporation with Israeli subsidiary Oramed Ltd.)
Reporting Period: Three months ended November 30, 2010 (Unaudited)
Business Stage: Development stage biotechnology company focused on orally ingestible insulin (ORMD-0801) and GLP-1 analogs.
Going Concern: The filing explicitly states substantial doubt regarding the company's ability to continue as a going concern due to accumulated losses and negative operating cash flows. Continued operations depend on securing additional financing.
Key Financial Metrics
| Metric | Nov 30, 2010 (3 Months) | Nov 30, 2009 (3 Months) | Inception to Nov 30, 2010 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(602,784) | $(612,793) | $(13,588,838) |
| Loss Per Share (Basic/Diluted) | $(0.01) | $(0.01) | N/A |
| Cash and Cash Equivalents | $1,101,283 | $1,146,128 | N/A |
| Total Assets | $1,358,505 | N/A | N/A |
| Total Liabilities | $544,434 | N/A | N/A |
| Stockholders' Equity | $814,071 | N/A | N/A |
| Operating Cash Flow | $(498,355) | $(170,738) | $(7,376,283) |
Note: The company has no revenue. Expenses are primarily Research & Development (R&D) and General & Administrative (G&A). R&D expenses for the quarter were $286,488 (net of grants), and G&A expenses were $315,129.
Material Changes vs. Prior Period
- Net Loss: Decreased slightly by approximately $10,000 compared to the prior year quarter ($602,784 vs. $612,793).
- R&D Expenses: Decreased from $332,485 in the prior year to $286,488, attributed to reduced manufacturing and clinical trial costs.
- G&A Expenses: Increased from $285,016 to $315,129, driven by higher consulting and stock-based compensation costs.
- Financing Activity: The company raised $300,000 in cash during the quarter via a private placement of 937,500 units (stock and warrants) at $0.32 per unit.
- Stock-Based Compensation: Total stock-based compensation expense for the quarter was $195,301, a significant non-cash charge.
Outlook, Risks, and Management Commentary
- Liquidity Needs: Management estimates a need for approximately $5.4 million to fund operations for the twelve months following December 1, 2010. Current cash of ~$1.1 million is insufficient.
- Financing Strategy: The company is actively pursuing public or private equity fundraising and relies on ongoing grants from the Office of the Chief Scientist (OCS) of Israel. A subsequent event noted a $2.05 million financing closed in December 2010/January 2011.
- Product Development:
- Oral Insulin (ORMD-0801): Completed exploratory trials in Type 1 diabetes patients with uncontrolled diabetes, showing encouraging results. Planning to file an Investigational New Drug (IND) application with the FDA.
- GLP-1 Analog: Human clinical trials commenced in Israel; results anticipated soon.
- Joint Venture: Established "Entera Bio Ltd." with D.N.A Biomedical Solutions to develop oral delivery drugs for osteoporosis. Oramed holds 50% interest.
- Risks: Substantial doubt about going concern; dependence on third-party suppliers for raw materials; uncertainty of patent issuance and enforcement; reliance on government grants which may require future royalties.
Investor Verification Checklist
- Capital Sufficiency: Verify the status of the $2.05 million financing mentioned in subsequent events and whether it covers the projected $5.4 million burn rate.
- Grant Obligations: Review the terms of OCS grants regarding future royalty payments (3% to 3.5% of sales, potentially up to 300% of grant amount if manufactured outside Israel).
- Joint Venture Terms: Assess the financial exposure regarding the Entera Bio Ltd. joint venture, specifically the potential $150,000 capital contribution requirement if third-party financing is not secured by June 1, 2011.
- Related Party Transactions: Review payments to Hadasit Medical Services and Dr. Miriam Kidron (Director/Officer) for consulting and clinical trial services.
- Stock Dilution: Monitor the impact of warrants issued in recent private placements (exercise price $0.50) on future share count.